Division of Cardiology, University of Colorado-Denver, 12605 E 16th Ave., Aurora, CO 80045, USA.
Circulation. 2012 Apr 3;125(13):1635-42. doi: 10.1161/CIRCULATIONAHA.111.068064. Epub 2012 Feb 29.
Despite a recent American Heart Association (AHA) consensus statement emphasizing the importance of resistant hypertension, the incidence and prognosis of this condition are largely unknown.
This retrospective cohort study in 2 integrated health plans included patients with incident hypertension in whom treatment was begun between 2002 and 2006. Patients were followed up for the development of resistant hypertension based on AHA criteria of uncontrolled blood pressure despite use of ≥3 antihypertensive medications, with data collected on prescription filling information and blood pressure measurement. We determined incident cardiovascular events (death or incident myocardial infarction, heart failure, stroke, or chronic kidney disease) in patients with and without resistant hypertension with adjustment for patient and clinical characteristics. Among 205 750 patients with incident hypertension, 1.9% developed resistant hypertension within a median of 1.5 years from initial treatment (0.7 cases per 100 person-years of follow-up). These patients were more often men, were older, and had higher rates of diabetes mellitus than nonresistant patients. Over 3.8 years of median follow-up, cardiovascular event rates were significantly higher in those with resistant hypertension (unadjusted 18.0% versus 13.5%, P<0.001). After adjustment for patient and clinical characteristics, resistant hypertension was associated with a higher risk of cardiovascular events (hazard ratio, 1.47; 95% confidence interval, 1.33-1.62).
Among patients with incident hypertension in whom treatment was begun, 1 in 50 patients developed resistant hypertension. Patients with resistant hypertension had an increased risk of cardiovascular events, which supports the need for greater efforts toward improving hypertension outcomes in this population.
尽管美国心脏协会(AHA)最近发布了一份共识声明,强调了耐药性高血压的重要性,但这种情况的发病率和预后在很大程度上仍不清楚。
这项回顾性队列研究纳入了 2 家综合医疗计划中的新发高血压患者,这些患者在 2002 年至 2006 年间开始接受治疗。根据 AHA 的标准,即尽管使用了≥3 种降压药物,但血压仍未得到控制,患者被随访耐药性高血压的发生情况,数据收集自处方填写信息和血压测量。我们根据患者和临床特征,调整了有和没有耐药性高血压患者的新发心血管事件(死亡或新发心肌梗死、心力衰竭、卒中和慢性肾脏病)的发生率。在 205750 名新发高血压患者中,有 1.9%的患者在初始治疗后 1.5 年内发展为耐药性高血压(每 100 人年随访中有 0.7 例)。这些患者中男性较多,年龄较大,且糖尿病患病率较高。在中位 3.8 年的随访期间,耐药性高血压患者的心血管事件发生率显著较高(未经调整的 18.0%比 13.5%,P<0.001)。在校正了患者和临床特征后,耐药性高血压与心血管事件风险增加相关(风险比,1.47;95%置信区间,1.33-1.62)。
在开始治疗的新发高血压患者中,每 50 名患者中就有 1 名患者会发展为耐药性高血压。耐药性高血压患者发生心血管事件的风险增加,这支持了在该人群中加强努力改善高血压治疗结局的必要性。